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Purpose/Objective: Inhomogeneities around lung tumours 
may reduce the accuracy of dose calculation by the planning 
system. The use of IMRT or VMAT can include small field 
segments which exacerbate these issues. Isotoxic IMRT is a 
multi-centre non-randomised feasibility study of isotoxic dose 
escalation using IMRT, for stage III non-small cell lung cancer 
patients. As part of the pre-trial QA, a dosimetry audit was 
undertaken to verify accurate delivery of the planning 
benchmark case. 
Materials and Methods: An ArcCheck diode array (Sun 
Nuclear) was used to measure fluences from the treatment 
delivery, and apply standard gamma analysis. Half of the 
Multiplug central insert was replaced by lung equivalent 
material (St. Bartholomew’s Hospital, London, UK) to 
simulate an inhomogeneous environment. Point and planar 
dose readings near the interface were acquired using a 
0.125cc ion chamber (PTW Semiflex), and GafChromic EBT3 
film (ISP) (Figure 1). 
 
 
Figure 1. Cross-section through ArcCheck, showing position of 
chamber point and film plane. 
 
Results: 2 pilot centres and 7 trial centres were visited, a 
total of 14 distinct combinations of planning and delivery 
system. Gamma analysis of the entry and exit dose fluence 
showed good agreement, with mean pass rates of 100% (range 
98-100%) and 99% (97-100%) for tolerances of 4%/3mm and 
3%/3mm respectively. Central point doses all agreed within 
±2.4%. Film gamma analysis gave mean pass rates of 96% (88-
100%) and 92% (78-99%) for tolerances of 4%/3mm and 
3%/3mm respectively. These are lower than for the array 
fluences because of proximity to the low density interface. 
Conclusions: This multi-centre audit of complex IMRT 
delivery provides confidence in the accuracy of a range of 
planning and delivery systems in an inhomogeneous 
environment. Along with other aspects of trial QA, it assures 
that trial outcomes will not be undermined by unintended 
variations in delivered doses.  
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Purpose/Objective: By applying the Mean Distance to 
Conformity (MDC) index proposed by Jena et al (1) to the 
dose distribution of a radiotherapy plan, the conformity of 
the 95% isodose line to the Planning Treatment Volume (PTV) 
can be measured, allowing both overdosing of normal tissue 
and underdosing of the target volume to be measured by the 
OverMDC and UnderMDC respectively. The aim of this study 
was therefore to analyse this aspect of treatment planning, 
in addition to volume of PTV and the treatment delivery 
method (3D conformal or Intensity Modulated Radiotherapy), 
and relate to patient outcome. 
Materials and Methods: The OverMDC and UnderMDC of the 
95% isodose line (V95% for 50Gy prescribed dose) to the PTV 
was calculated using a Matlab script based in CERR (2) for 97 
patients from the SCOPE 1 trial (a National Cancer Research 
Institute (NCRI) and Cancer Research UK (CRUK) funded Phase 
II/III two arm trial of definitive chemoradiotherapy (dCRT) in 
oesophageal cancer) (3). Kaplan-Meier and multivariate 
analysis was undertaken in EUCLID (4) with further tests in 
Microsoft Excel and IBM’s SPSS.  
Results: A statistically significant breakpoint in the overall 
survival data, independent of cetuximab, was found 
according to OverMDC metric (0.44cm, p<0.05). This was not 
the case with UnderMDC. There was a statistically significant 
difference in PTV volume either side of the OverMDC 
breakpoint (Mann Whitney p<0.001). There was a statistically 
significant difference in OverMDC value dependent on the 
treatment delivery method (mean IMRT=0.21cm, mean 3D-
CRT=0.41cm Mann Whitney p<0.001). OverMDC did not 
remain significant in a multivariate analysis that included 
age, sex, staging, tumour type, position, PTV volume and 
GTV length. 
Conclusions: We have shown in univariate analysis that a 
patient’s OverMDC has a significant correlation with overall 
survival, independent of Cetuximab. OverMDC is strongly 
related to IMRT and to a lesser extent with PTV volume. We 
recommend careful attention to all aspects of plan quality, 
not just adequate coverage of the PTV.  
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Purpose/Objective: Pre-treatment imaging based on 
ultrasound (US) images was first developed using 
transabdominal probes but several issues linked to image 
quality and probe pressure1 were reported. The aim of this 
work was to evaluate a non-invasive transperineal (TP) US 
probe comparing its registration results with cone beam CT 
(CBCT) on patients treated for a prostate cancer, with 
prostate in situ or after prostatectomy.  
Materials and Methods: 10 prostate patients (cohort A) and 
14 post-prostatectomy patients (cohort B) were imaged with 
the TP probe (Clarity, Elekta), which acquires 3D images 
using an automated motorized sweep. During the planning CT 
session, a reference US (USref) image was acquired with the 
patient in the same position as that of the CT acquisition. A 
reference positioning volume (RPV) was delineated on the 
USref image (Figure 1). For each treatment session, a daily US 
(USday) image was acquired and manually registered on the 
USref image using a RPV projection. A CBCT image was 
acquired right after and registered on the reference CT. The 
differences between CBCT and TP-US shifts were analysed on 
320 and 453 paired USday/USref and CBCT/CT images for the 
cohorts A and B, respectively. Finally, the systematic 
difference found between CBCT and US shifts was 
retrospectively calculated on the first 5 sessions and applied 
to the US shifts of the following sessions. 
  
 
 
Results: The US system was well tolerated by the patients. 
All images were of good quality for the registration of the 
two cohorts. On the raw data, shifts agreements at ± 5 mm 
were above 80 %, with the best agreement obtained in the 
lateral direction for both localizations (≥ 97.6 %). Average 
differences between the 2 modalities were 2.2 ± 3.2 mm, -
0.2 ± 2.5 mm and -0.3 ± 2.7 mm for the cohort A, and 1.5 ± 
2.6 mm, -1.6 ± 3.2 mm and -0.5 ± 2.3 mm for the cohort B, in 
the axial, longitudinal and lateral directions respectively. 
These results were comparable to other inter modalities, 
e.g., CBCT soft tissue registration versus fiducial markers 
with MV-EPI registration2. Correcting the systematic shifts 
between the 2 image modalities on the base of the first 5 
fractions enabled the percentage of agreement to be greater 
than 93 % for all directions and localizations and the average 
differences to be close to 0 mm (≤ 0.3 mm whatever the 
direction or localization). Therefore, correcting systematic 
shifts drastically improved the results. 
Conclusions: TP-US based localization of the prostate or the 
prostate bed is a feasible method to ensure accurate delivery 
of treatment plans. This device represents an attractive 
alternative to invasive and/or irradiating imaging modalities.  
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